HOME > Business Wire > Article
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
LJI and RevolKa will Research Nex-gen Vaccine Antigens by using AI-driven Protein Engineering Platform
TOKYO--( BUSINESS WIRE )-- RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a research collaboration to create antigens for the next-generation vaccines to deliver innovative solutions to unmet medical need in infectious diseases. RevolKa has a robust directed protein evolution technology integrated with artificial intelligence (AI), called aiProtein®. LJI and RevolKa will synergize LJI’s deep knowledge of immunology and RevolKa’s power of AI-driven protein engineering. Details of this collaboration and financial terms were not disclosed.
About aiProtein® Technology
RevolKa’s proprietary technology, aiProtein® is an AI-assisted directed evolution of proteins. Naturally occurring protein is a linear polymer of amino acids and their derivatives, which folds into a tertial structure through internal complex atomic interactions to show biological function. Proteins have evolved to biologically functional molecules over hundreds of millions of years. The relationship between protein sequence, structure, and function in those highly functioned molecules remains poorly understood to rationally design a protein sequence for a particular function. Our AI engine is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function. Furthermore, aiProtein® can evolve more than two functions simultaneously. This technology is a powerful and cost-effective tool for the creation of novel and highly-optimized proteins for pharmaceutical and industrial uses.
About RevolKa Ltd.
RevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts in biotechnology and artificial intelligence. Our mission is to create novel proteins useful for therapeutics and industries by using our own proprietary technology platform, aiProtein® to contribute to human well-being. The name "RevolKa" is derived from the Latin word for evolution, "evolutio” and the Ainu (an indigenous Japanese people) word for raise, “reska”. RevolKa’s headquarters are located in Tokyo, Japan with laboratories located in Sendai. The company’s investors include D3 LLC, DEEPCORE Inc., Tohoku University Venture Partners, and SBI investment Co., Ltd. For more information, visit https://www.revolka.com/en/ .
About La Jolla Institute for Immunology
The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system to that we may apply to that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: Life without Disease®. For more information, visit https://www.lji.org/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408374466/en/
Source: RevolKa Ltd.
Business Wire
- 05/03 00:00 The K-Content Media Channel 'Kitto' to Make an Official Launch in Japan
- 05/02 18:04 NPCI International Partners with Bank of Namibia for Deploying India...
- 05/02 18:00 Asahi Kasei Bioprocess to Unveil THESYS™ ACS ERGO Synthesis Column a...
- 05/01 03:00 Fast Fitness Japan Obtains Master Franchisee Rights for Anytime Fitnes...
- 04/30 20:05 Quantum Announces Expanded Global Partnership Model to Grow Presence i...
- 04/30 12:42 Eastman and Lubrizol Collaborate to Enhance TPE Overmolding Adhesion W...
- 04/30 12:00 Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clini...
- 04/30 11:00 PeptiDream Announces Expansion of Peptide Discovery Collaboration with...
- 04/30 06:00 USound and Minami Sign Partnership to Facilitate New Collaborations wi...
- 04/30 05:45 Opening of the 2024 International Horticulture Goyang Korea “A Color...
- 04/29 23:30 Palliser Capital Submits Binding AGM Resolution After Keisei Board Den...
- 04/29 16:00 Poxel Provides a Financial Update for the First Quarter 2024 and Annou...
- 04/29 14:00 PKSHA develops advanced Large Language Models in collaboration with Mi...
- 04/29 06:30 NextPower V ESG Reaches $745 Million To Date
- 04/29 06:30 H2SITE’s AMMONIA to H2POWER Technology Receives Approval in Principl...
- 04/29 06:00 ENHERTU® Demonstrated Statistically Significant and Clinically Meanin...
- 04/29 01:00 DTEN’s Next Generation Video Conferencing and Collaboration Device f...
- 04/26 14:44 C2N Diagnostics Expands Into Japan Through Mediford Corporation Partne...
- 04/26 12:30 Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously T...
- 04/26 06:24 Kyocera Announces Consolidated Financial Results for Year Ended March ...
- 04/26 06:10 Mitsubishi Electric Announces Consolidated Financial Results for Fisca...
- 04/26 03:30 O.P. Jindal Global University’s Vice Chancellor, Prof. C. Raj Kumar ...
- 04/25 13:00 DIC Algae Oil Sulfurized Extreme Pressure Additives Present Promising ...
- 04/25 00:00 Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada
- 04/25 00:00 Renesas Reports Financial Results for the First Quarter Ended March 31...
- 04/25 00:00 Renesas Announces Consolidated Forecasts
- 04/24 22:00 Nihon Global Growth Partners Submits Shareholder Proposals for Conside...
- 04/24 10:00 SES AI, Hyundai Motor and Kia Agree to Enter the Next Phase of Their J...
- 04/24 07:30 Palliser Capital Proposes Advisory Resolution to Give Shareholders a V...
- 04/24 01:30 Kura Sushi Global Flagship Store Ginza to open on Thursday, April 25, ...